We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | NYSE:TEVA | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.76 | 0 | 01:00:00 |
From May 2019 to May 2024
By Adam Clark
Shield Therapeutics PLC (STX.LN) said Monday that Teva Pharmaceutical Industries Ltd. (TEVA) has filed a notice of appeal against the recent grant of a European patent for Shield's Feraccru iron-deficiency treatment.
Shield said Teva opposed its patent covering a "process for preparing an iron hydroxypyrone."
No data has been set for the hearing. Shield said it will defend its intellectual property.
Write to Adam Clark at adam.clark@dowjones.com; @AdamDowJones
(END) Dow Jones Newswires
June 03, 2019 03:12 ET (07:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Teva Pharmaceutical Indu... Chart |
1 Month Teva Pharmaceutical Indu... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
